Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis.
Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis.
复制标题
血浆 microRNA-133a 是急性心肌梗塞和潜在冠状动脉狭窄的新标志物
DOI：
10.1186/1479-5876-11-222
复制
发表时间：
2013-09-23
影响因子：
7.4
通讯作者：
Wang DW
中科院分区：
文献类型：
--
作者：
Wang F;Long G;Zhao C;Li H;Chaugai S;Wang Y;Chen C;Wang DW
背景研究表明，在心血管疾病中，miR-133 a可从受损心肌释放到血液中。然而，急性心肌梗死（AMI）早期循环miR-133 a水平的动态变化以及miR-133 a与冠心病（CHD）患者冠状动脉狭窄程度的相关性尚不清楚。（包括13例AMI患者，176名心绞痛患者和127名对照受试者）入组研究循环miR-121的表达水平。研究了心肌缺血患者血浆miR-133 a水平以及血浆miR-133 a水平与冠状动脉狭窄程度的关系。通过实时定量PCR检测参与者的血浆miR-133 a水平。同时，通过ELISA测定血浆心肌肌钙蛋白I（cTnI）浓度。结果显示，AMI患者循环miR-133 a水平呈时间依赖性升高，在AMI症状发作后21.6 ± 4.5 h达到峰值72.1倍，与血浆cTnI水平变化趋势相似。冠心病患者血浆miR-133 a水平明显高于对照组。重要的是，循环miR-133 a的水平与冠状动脉狭窄的严重程度正相关。受试者工作特征（ROC）分析显示，循环miR-133 a对CHD的诊断准确性较高，AUC为0.918（95%可信区间0.877-0.960）。miR-133 a水平的升高可用于预测冠心病患者冠状动脉病变的存在和严重程度。
BackgroundPrevious study demonstrated that miR-133a was released into blood from injured myocardium in cardiovascular diseases. However, the dynamic change of circulating miR-133a level in the early phase of acute myocardial infarction (AMI) and the correlation between miR-133a and severity of coronary stenosis in coronary heart disease (CHD) patients are not clear.Methods and resultsThree different cohorts (including 13 AMI patients, 176 angina pectoris patients and 127 control subjects) were enrolled to investigate the expression levels of circulating miR-133a in patients with myocardial ischemia and also the relationship between plasma miR-133a and severity of coronary stenosis. Plasma miR-133a levels of participants were examined by real-time quantitative PCR. Simultaneously, plasma cardiac troponin I (cTnI) concentrations were measured by ELISA assays. The results showed that circulating miR-133a level was significantly increased in AMI patients in time-dependent manner, and achieved a 72.1 fold peak at 21.6 ± 4.5 hours after the onset of AMI symptoms and exhibited a similar trend to plasma cTnI level. We also found that plasma miR-133a levels were higher in CHD patients than control group. Importantly, the levels of circulating miR-133a positively correlated with the severities of the coronary artery stenosis. Receiver operating characteristic (ROC) analysis revealed that circulating miR-133a had considerable diagnostic accuracy for CHD with an AUC of 0.918 (95% confidence interval 0.877-0.960).ConclusionsCirculating miR-133a may be a new biomarker for AMI and as a potential diagnostic tool. And increased miR-133a level may be used to predict both the presence and severity of coronary lesions in CHD patients.